In light of the findings presented here, preventing PML-II degradation by targeting post-translational proteasome-dependent mechanisms of PML turnover, or increasing PML-II levels by other means, should sensitize cancer cells to IFN-induced cell death and provide a useful additional approach to therapy. Here, IFNA1 is linked to cancer.